Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASRT NASDAQ:AZRX NASDAQ:MBRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$23.470.0%$20.97$8.61▼$23.49$151.66M0.52206,150 shs297,794 shsAZRXAzurRx BioPharma$2.08-3.7%$4.04$3.36▼$26.30$19.40M1.51628,703 shs126,966 shsMBRXMoleculin Biotech$2.70+8.0%$2.45$1.79▼$24.00$14.41M1.77181,818 shs193,132 shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio+0.09%+0.04%+5.01%+102.07%+136.85%AZRXAzurRx BioPharma0.00%0.00%0.00%-9.17%+288.64%MBRXMoleculin Biotech+3.73%+1.63%+2.46%+21.95%-84.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$23.470.0%$20.97$8.61▼$23.49$151.66M0.52206,150 shs297,794 shsAZRXAzurRx BioPharma$2.08-3.7%$4.04$3.36▼$26.30$19.40M1.51628,703 shs126,966 shsMBRXMoleculin Biotech$2.70+8.0%$2.45$1.79▼$24.00$14.41M1.77181,818 shs193,132 shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio+0.09%+0.04%+5.01%+102.07%+136.85%AZRXAzurRx BioPharma0.00%0.00%0.00%-9.17%+288.64%MBRXMoleculin Biotech+3.73%+1.63%+2.46%+21.95%-84.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASRTAssertio 1.80Reduce$22.65-3.49% DownsideAZRXAzurRx BioPharma 0.00N/AN/AN/AMBRXMoleculin Biotech 2.33Hold$22.00714.81% UpsideCurrent Analyst Ratings BreakdownLatest MBRX, AZRX, and ASRT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026ASRTAssertio Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$21.80 ➝ $23.505/5/2026ASRTAssertio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$18.00 ➝ $21.804/21/2026MBRXMoleculin Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026ASRTAssertio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026ASRTAssertio Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/9/2026ASRTAssertio Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$45.00 ➝ $18.004/9/2026ASRTAssertio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$35.00 ➝ $18.003/24/2026MBRXMoleculin Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.00(Data available from 6/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASRTAssertio$102.16M1.48$0.02 per share1,434.84$14.63 per share1.60AZRXAzurRx BioPharmaN/AN/AN/AN/A($0.76) per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$4.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASRTAssertio-$30.38M-$5.69N/A21.14N/A-34.94%-38.72%-13.32%7/30/2026 (Estimated)AZRXAzurRx BioPharma-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/AMBRXMoleculin Biotech-$33.56M-$17.98N/AN/AN/AN/AN/A-70.93%8/11/2026 (Estimated)Latest MBRX, AZRX, and ASRT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026MBRXMoleculin Biotech-$2.3333-$3.54-$1.2067-$3.54N/AN/A5/8/2026Q1 2026ASRTAssertio-$2.1025-$2.93-$0.8275-$2.93$8.97 million$9.93 million3/16/2026Q4 2025ASRTAssertio-$3.05-$1.86+$1.19-$1.86$6.20 million$13.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASRTAssertioN/AN/AN/AN/AN/AAZRXAzurRx BioPharmaN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASRTAssertio0.521.821.57AZRXAzurRx BioPharmaN/A1.331.33MBRXMoleculin BiotechN/A1.381.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASRTAssertio48.96%AZRXAzurRx BioPharma6.27%MBRXMoleculin Biotech15.52%Insider OwnershipCompanyInsider OwnershipASRTAssertio5.70%AZRXAzurRx BioPharma7.30%MBRXMoleculin Biotech1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASRTAssertio206.46 million6.09 millionOptionableAZRXAzurRx BioPharma129.33 million8.65 millionNot OptionableMBRXMoleculin Biotech205.34 million5.28 millionNot OptionableMBRX, AZRX, and ASRT HeadlinesRecent News About These CompaniesAcumen Pharmaceuticals (NASDAQ:ABOS) & Moleculin Biotech (NASDAQ:MBRX) Financial SurveyJune 10 at 5:24 AM | americanbankingnews.comIndependent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AMLJune 5, 2026 | globenewswire.comMoleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” SegmentJune 4, 2026 | globenewswire.comMoleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline LimitsMay 29, 2026 | globenewswire.comMoleculin Biotech Releases Updated Investor Information PresentationMay 26, 2026 | tipranks.comMoleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for AnnamycinMay 21, 2026 | globenewswire.comMoleculin Biotech Reports Promising Early Results in MIRACLE Trial for AML Treatment with 40% Composite Complete Remission RateMay 15, 2026 | quiverquant.comQMoleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE TrialMay 15, 2026 | globenewswire.comMoleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical BenchmarksMay 13, 2026 | globenewswire.comIndependent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline LimitsMay 12, 2026 | globenewswire.comMoleculin Biotech Secures Hong Kong Patent for Annamycin Method Ahead of Phase 3 Clinical Data ReleaseMay 8, 2026 | quiverquant.comQMoleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of AnnamycinMay 8, 2026 | globenewswire.comMoleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026April 24, 2026 | markets.businessinsider.comMoleculin Biotech, Inc. Reports Promising Preclinical Results for Annamycin in Pancreatic Cancer TreatmentApril 23, 2026 | quiverquant.comQMoleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026April 23, 2026 | globenewswire.comMoleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual MeetingApril 21, 2026 | globenewswire.comMoleculin Biotech Stockholders Approve Warrant Share IssuanceApril 15, 2026 | tipranks.comMoleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic ProfileApril 7, 2026 | markets.businessinsider.comMoleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic ProfileApril 7, 2026 | globenewswire.comMoleculin Biotech (MBRX) price target decreased by 13.70% to 21.42March 28, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBRX, AZRX, and ASRT Company DescriptionsAssertio NASDAQ:ASRT$23.47 -0.01 (-0.04%) Closing price 04:00 PM EasternExtended Trading$23.47 0.00 (-0.02%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.AzurRx BioPharma NASDAQ:AZRXAzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.Moleculin Biotech NASDAQ:MBRX$2.70 +0.20 (+8.00%) Closing price 04:00 PM EasternExtended Trading$2.72 +0.02 (+0.89%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress SpaceX IPO Fears Are Overblown, But the AI Bet Is Real The Biggest Opportunity From SpaceX’s IPO May Surprise You NVIDIA’s Outlook Gains Momentum: Stock Price to Follow Chewy’s Growth Engine Is Stronger Than the Market Thinks Casey’s Is Looking Like a Hot Buy as Growth, Buybacks, and Guidance Align Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
